表紙
市場調査レポート

イネ科花粉症:パイプライン製品の分析

Grass Pollen Allergy - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 200453
出版日 ページ情報 英文 59 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
イネ科花粉症:パイプライン製品の分析 Grass Pollen Allergy - Pipeline Review, H1 2016
出版日: 2016年03月22日 ページ情報: 英文 59 Pages
概要

イネ科花粉アレルギーは、イネ科植物の花粉に接触してすぐに発生する反応のことを指します。主な症状・徴候には、皮膚の反応(じんましん・発赤・腫れなど)、口・喉の辺りのかゆみ・刺痛、喉の硬直、)、息切れ、喘鳴、鼻水などが挙げられます。主な疾病素質には年齢や家族歴、他のアレルギー体質などがあります。

当レポートでは、世界各国でのイネ科植物による花粉症の治療用パイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

イネ科花粉症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

イネ科花粉症:企業で開発中の治療薬

イネ科花粉症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

イネ科花粉症:企業で開発中の製品

イネ科花粉症の治療薬開発に従事している企業

  • ALK-Abello A/S
  • Allergy Therapeutics Plc
  • Anergis SA
  • Biomay AG
  • BioTech Tools s.a.
  • Circassia Pharmaceuticals Plc
  • HAL Allergy BV
  • Laboratorios LETI S.L.
  • Roxall Medizin GmbH
  • 塩野義製薬

イネ科花粉症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • AllerG
  • イネ科花粉症・喘息・アレルギー性鼻炎結膜炎のためのアレルゲンエキス
  • BM-32
  • clustoid wiesenlieschgras
  • gp-ASIT
  • Pollinex Quattro Grass
  • S-555739、など

イネ科花粉症:最近のパイプライン動向

イネ科花粉症:休止中のプロジェクト

イネ科花粉症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7765IDB

Summary

Global Markets Direct's, 'Grass Pollen Allergy - Pipeline Review, H1 2016', provides an overview of the Grass Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Grass Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy
  • The report reviews pipeline therapeutics for Grass Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Grass Pollen Allergy therapeutics and enlists all their major and minor projects
  • The report assesses Grass Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Grass Pollen Allergy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Grass Pollen Allergy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Grass Pollen Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Grass Pollen Allergy Overview
  • Therapeutics Development
    • Pipeline Products for Grass Pollen Allergy - Overview
  • Grass Pollen Allergy - Therapeutics under Development by Companies
  • Grass Pollen Allergy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Grass Pollen Allergy - Products under Development by Companies
  • Grass Pollen Allergy - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Allergy Therapeutics Plc
    • Anergis SA
    • Biomay AG
    • Circassia Pharmaceuticals Plc
    • HAL Allergy BV
    • Roxall Medizin GmbH
    • Shionogi & Co., Ltd.
  • Grass Pollen Allergy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AllerG - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Grass Allergy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • asapiprant - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BM-32 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • clustoid wiesenlieschgras - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pollinex Quattro Grass - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Grass Pollen Allergy - Recent Pipeline Updates
  • Grass Pollen Allergy - Dormant Projects
  • Grass Pollen Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Feb 18, 2016: Allergy Therapeutics Announces Patient enrolment completed in US Phase IIb study of GrassMATAMPL
      • Jan 14, 2016: ALK announces top-line results from the five-year landmark GRAZAX Asthma Prevention trial in children
      • Jun 03, 2015: Positive phase IIb data on BM32, Biomay's innovative grass pollen allergy vaccine will be reported in hot topic session at major international scientific conference.
      • Jan 28, 2015: Biomay reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32
      • Apr 14, 2014: ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK
      • Feb 18, 2014: Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study
      • Feb 03, 2014: Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)
      • Dec 16, 2013: Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32
      • Dec 12, 2013: FDA Advisory Committee meeting unanimously recommends approval of GRASTEK
      • Dec 10, 2013: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the grass sublingual AIT tablet
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Grass Pollen Allergy, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Grass Pollen Allergy - Pipeline by ALK-Abello A/S, H1 2016
  • Grass Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H1 2016
  • Grass Pollen Allergy - Pipeline by Anergis SA, H1 2016
  • Grass Pollen Allergy - Pipeline by Biomay AG, H1 2016
  • Grass Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H1 2016
  • Grass Pollen Allergy - Pipeline by HAL Allergy BV, H1 2016
  • Grass Pollen Allergy - Pipeline by Roxall Medizin GmbH, H1 2016
  • Grass Pollen Allergy - Pipeline by Shionogi & Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Grass Pollen Allergy Therapeutics - Recent Pipeline Updates, H1 2016
  • Grass Pollen Allergy - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Grass Pollen Allergy, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top